gene screening in ALS - frequency of mutations, patients' attitudes to genetic information and transition to tofersen treatment in a multi-center program.

OBJECTIVE

To report the frequency of pathogenic gene variants in a screening program in amyotrophic lateral sclerosis (ALS), and the clinical practice of transition to an expanded access program (EAP) of tofersen treatment.

METHODS

From October 2021 to February 2024, at 11 ALS centers in Germany genetic testing for , , and was performed. Patients were offered to opt for notification either about all genetic variants or variants relevant for tofersen therapy. The transition to the EAP with tofersen was assessed.

RESULTS

1935 patients were screened (94.7% sporadic ALS). 48.8% ( = 928) opted for notification of treatment-relevant information. Genetic variants were found as follows: (likely) pathogenic variants (class 4/5) 1.8% ( = 34), variants of unknown significance (class 3) 0.8% (= 16), (class 4/5) 0.9% (= 17) (class 4/5) 1.3% ( = 25), hexanucleotide repeat expansion 7.0% (= 135). In -ALS (encompassing class 3-5 variants, = 50), 68.0% ( = 34) reported a negative family history. 74.0% (= 37) of -ALS patients - which represent 1.9% of all participants of the screening program - were transitioned to tofersen. Median duration from start of genetic testing to treatment was 94 days (57 to 295 days). Eight patients declined treatment whereas five individuals died before initiation of therapy.

CONCLUSION

The finding of variants in patients with a negative family history underscores the need for a broad genetic screening in ALS. In -ALS, the treatment option with tofersen was mostly utilized. The wide range in the transition time to tofersen calls for a -ALS management program.